Feasibility, Visual Outcomes and Severity-Stratified Response to Pre-operative Intravitreal Bevacizumab Before Vitrectomy in Proliferative Diabetic Retinopathy
DOI:
https://doi.org/10.37275/bsm.v10i3.1664Keywords:
Bevacizumab, Feasibility studies, Pars plana vitrectomy, Proliferative diabetic retinopathy, Vitreous hemorrhageAbstract
Background: Proliferative diabetic retinopathy is a leading cause of vision loss in working-age Indonesians, and pre-operative anti-vascular endothelial growth factor therapy has been proposed to make vitrectomy safer, yet Southeast Asian trial evidence is almost absent.
Objective: To assess the feasibility, visual outcomes, and severity-stratified response to pre-operative intravitreal bevacizumab before 23-gauge pars plana vitrectomy in patients with proliferative diabetic retinopathy.
Methods: In a single-centre, single-blind pilot randomised controlled trial at the Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya/ Dr. Mohammad Hoesin Central General Hospital, Palembang (July–November 2025), 21 adults with proliferative diabetic retinopathy and non-clearing vitreous haemorrhage were allocated 1:1, stratified by haemorrhage severity, to intravitreal bevacizumab 1.25 mg/0.05 mL given 3–7 days before 23-gauge pars plana vitrectomy (n = 11) or to vitrectomy alone (n = 10). Progression criteria were pre-specified; the clinical outcome was best-corrected visual acuity change in LogMAR at one week.
Results: All progression criteria fell in the green zone (recruitment 95.5%, 95% CI 78.2–99.2; retention and adherence 100%). Bevacizumab-treated eyes gained more vision, but imprecisely (Hodges–Lehmann shift 0.35 LogMAR, envelope 0.10 to 0.50; Hedges' g 0.65), the trial retaining only 14.8% power for the observed difference. Baseline vitreous haemorrhage severity dominated visual gain (adjusted B -0.397 LogMAR per grade, 95% CI -0.639 to -0.155; Cochran–Armitage trend p = 0.015).
Conclusion: Pre-operative bevacizumab is feasible in an Indonesian tertiary centre and warrants a severity-stratified multicentre trial.
Authors
- Ramzi Amin1*
- Fajar Prasetya1
- Abdul Karim Ansyori1
- 1Department of Ophthalmology, Faculty of Medicine, Universitas Sriwijaya/ Dr. Mohammad Hoesin Central General Hospital, Palembang, Indonesia
Corresponding author Ramzi Amin — ramziamin20@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Ramzi Amin, Fajar Prasetya, Abdul Karim Ansyori
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
